Raptiva Sales Suspension Recommended in Europe After Reports of Brain InfectionsFeb 20, 2009 | Parker Waichman LLP
On the same day U.S. regulators warned that the psoriasis drug Raptiva had been linked to three fatal case of a rare brain infection, their counterparts in the European Union have recommended sales of the drug be suspended. In a statement, advisers to the European Medicines Agency (EMEA) said that in light of the deaths, Raptiva's benefits do not outweigh its risks.
Raptiva is an injectable drug that was approved by the U.S. Food & Drug Administration (FDA) in 2003 to treat moderate to severe plaque psoriasis. Raptiva works by blocking the activation of certain immune cells called T cells, and the migration of those cells into the skin. However, by suppressing the body’s natural defense system, it can also increase the risk of serious infections and malignancies in patients.
Yesterday, the FDA said that it had confirmed three fatal cases of the rare brain infection, progressive multifocal leukoencephalopathy (PML) in Raptiva patients. The agency also said that it had learned of a suspected PML death in a fourth person treated with Raptiva. The FDA said it was currently reviewing the latest information regarding Raptiva and PML, and is taking action to ensure that the risks of Raptiva do not outweigh its benefits.
Meanwhile, the EMEAs Committee for Medicinal Products for Human Use said yesterday it had conducted a benefit/risk review of the drug, and concluded Raptiva's benefits no longer outweigh its risks. The European Commission will consider the advice. It usually follows EMEA recommendations.
Considering the cloud that Raptiva is now under, one analyst told Reuters that it is becoming. "increasingly likely" Raptiva would be pulled from the U.S. market. In October 2008, the FDA had already required Genentech to place a Boxed Warning on the Raptiva label regarding the drugs' risk of PML and other infectious diseases.
PML attacks the brain and central nervous system and is usually fatal. It is caused by a polyomavirus, called the JC virus. The JC virus is often acquired during childhood. Most adults have been infected with the JC virus but do not develop PML. Symptoms include vision problems, loss of coordination, and memory loss. Patients who survive the disease are often permanently disabled.
Other drugs that suppress the immune system have also been linked to PML. Last September, Genentech revised a warning on Rituxan to reflect the case of a rheumatoid arthritis patient who was treated with the medicine and died from PML.
Last summer, the FDA warned that the same brain disease had been associated with Tysabri, a drug for multiple sclerosis. The FDA warning was prompted by reports of two European MS patients undergoing Tysabri monotherapy had developed PML. In the U.S., Tysabri was taken off the market in 2005 after three patients in clinical trials developed PML. But the drug was reapproved in 2006, although it was subject to restrictions.